GenomeWeb Webinar: An Agentic AI Approach to Predicting Immunotherapy Response

Immune checkpoint inhibitors have transformed cancer care, yet only about 1 in 5 patients respond to PD-1 blockade. Predicting who will respond remains one of oncology's biggest unsolved challenges.

In this webinar, scientists from Mithrl and Elephas will share how combining functional tumor profiling with agentic AI can reduce that uncertainty, integrating real-time cytokine data from live tumor biopsies with large-scale genomic datasets to reveal the immune signatures that drive response. Attendees will get a firsthand look at how this approach was applied across 131 human tumor specimens and what it uncovered.

Erika von Euw is vice president of scientific affairs at Elephas Biosciences, where she oversees scientific affairs, strategic collaborations, and external scientific engagement to advance precision oncology. She holds a doctorate in translational oncology from the University of Buenos Aires and completed postdoctoral training at the University of California, Los Angeles. With more than 20 years of experience across academia and biotechnology, von Euw has extensive expertise in cancer immunology, cell and gene therapies, translational research, biomarker development, and oncology drug development. She also holds an executive MBA from Rochester Institute of Technology. In addition to her industry leadership, von Euw is cofounder and chair of Women In Bio Los Angeles, where she is dedicated to advancing leadership opportunities for women in the life sciences.

Ada Shaw, head of scientific partnerships at Mithrl, has experience that spans computational biology, software engineering, and biopharma strategy. Shaw earned her doctorate in applied mathematics at Harvard University, where she developed probabilistic models for multifunctional protein design. She brings extensive expertise in protein engineering, machine learning, and deep learning. She has collaborated with leading research institutions and advised therapeutics companies on strategic innovation. At Mithrl, she applies computational biology, AI, and pipeline engineering to analyze high-dimensional biological data, develop models, and generate insights that help researchers make faster, more informed decisions. Additionally, Shaw's partnership work with Elephas and other innovative organizations is pushing the boundaries of translational research and drug discovery.